Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00877188 Completed - Breast Cancer Clinical Trials

Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors

Start date: January 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects of a combined aerobic and resistance exercise program in breast cancer survivors.

NCT ID: NCT00876486 Completed - Breast Cancer Clinical Trials

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

Start date: December 2008
Phase: Phase 3
Study type: Interventional

Phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in subjects with recurrent or metastatic breast cancer.

NCT ID: NCT00876395 Completed - Breast Cancer Clinical Trials

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

BOLERO-1
Start date: September 10, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.

NCT ID: NCT00876070 Completed - Clinical trials for Metastatic Breast Cancer

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

Start date: November 2008
Phase: N/A
Study type: Observational

This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.

NCT ID: NCT00875979 Completed - Clinical trials for Metastatic Breast Cancer

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by intravenous (IV) infusion in combination with pertuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced or metastatic breast cancer who had previously received trastuzumab.

NCT ID: NCT00875355 Recruiting - Breast Cancer Clinical Trials

Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer

Start date: November 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given alone or together with temozolomide in treating brain metastases secondary to breast cancer. PURPOSE: This randomized phase II trial is studying how well radiation therapy given together with temozolomide works compared with radiation therapy given alone in treating women with brain metastases and breast cancer.

NCT ID: NCT00875238 Completed - Breast Cancer Clinical Trials

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

PACE in BC
Start date: June 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects. PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.

NCT ID: NCT00874211 Completed - Breast Cancer Clinical Trials

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Start date: December 2008
Phase:
Study type: Observational

RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care. PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases.

NCT ID: NCT00874146 Recruiting - Clinical trials for Advanced Breast Cancer

Level of HER2-neu Gene Amplification an Response to Trastuzumab

Start date: March 2009
Phase: N/A
Study type: Observational

Primary objective of the study is to evaluate the correlation between level of HER2-neu gene amplification evalued by dual-color Fluorescent in-situ hybridization (FISH) test and time to progression (TTP) in patients with HER2-positive advanced breast cancer treated with trastuzumab-containing regimens.

NCT ID: NCT00873808 Withdrawn - Breast Cancer Clinical Trials

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Start date: October 2008
Phase: N/A
Study type: Observational

RATIONALE: Gathering information over time from imaging and laboratory tests of women receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline hydrochloride can mark the new growth of the bone, so it may be seen better under a microscope. PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer enrolled on clinical trial SWOG-S0307.